Replies to post #181655 on Biotech Values

[DewDiligence]

The clock is ticking on ENTA’s decision whether to opt in for US profit sharing on the ABT-493/ABT-530 regimen. I don’t know the exact decision deadline, but it has to be soon insofar as the phase-2b study has begun (#msg-106122063).